|
Title
|
Published
|
Price
|
|
Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response
By: CHI Insight Pharma Reports
The human immune system can go awry, either attacking an individual’s body or producing an exag-gerated response to a foreign substance that is normally benign. In these situations, immunotherapies are needed to balance or suppress
|
more...
|
11/1/2009
|
$3,750.00
|
|
Immunotherapies and Vaccines for Nontraditional Indications
By: CHI Insight Pharma Reports
Novel applications of immunotherapies and vaccines beyond prevention and treatment of infectious diseases and cancer are reviewed. Those discussed typically target molecules not normally targeted by the immune system. This report:
Covers a wide
|
more...
|
10/1/2009
|
$2,995.00
|
|
Ion Channel Modulator Pipelines: Targets and Agents in Development
By: CHI Insight Pharma Reports
Ion channels represent a significant opportunity to address an underexploited class of therapeutic targets. Nearly 150 novel ion channel modulators are reported to be in clinical development. This report examines:
Ion channel modulators in
|
more...
|
9/1/2009
|
$3,750.00
|
|
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment
By: CHI Insight Pharma Reports
In the nearly 35 years since the first process for creating mAbs was introduced, they have remained a centerpiece of the growing biotechnology industry. Thirty therapeutic mAbs have been approved around the world, including
|
more...
|
8/1/2009
|
$3,750.00
|
|
Outsourcing Preclinical Studies to China
By: CHI Insight Pharma Reports
Within the past several years, a number of government labs as well as private and joint venture CRO’s have or will soon offer preclinical GLP study services to Western clients. This report, built on discussions
|
more...
|
7/1/2009
|
$2,995.00
|
|
Data Mining in Drug Development and Translational Medicine
By: CHI Insight Pharma Reports
The biopharmaceutical industry is grappling not only with sheer data volume but with the ability of researchers to extract information through identification and contextual analysis of those data that are relevant to a particular set
|
more...
|
7/1/2009
|
$2,995.00
|
|
Next-Generation Sequencing: Solving the Genome
By: CHI Insight Pharma Reports
Next-generation sequencing (NGS) technologies are advancing in quality and applications diversity at a breathtaking pace. The market is diversifying strongly into labs without previous involvement in sequencing. This report examines:
Current NGS platforms and
|
more...
|
6/1/2009
|
$2,995.00
|
|
Pharmacogenomics: Delivering on the Promise
By: CHI Insight Pharma Reports
Pharmacogenomics (PGx) is often considered “the great new wave” in medicine, promising better, safer, and more affordable healthcare. Yet its adoption and widespread use in the clinic is up against some tremendous challenges. This report
|
more...
|
6/1/2009
|
$2,995.00
|
|
Bioinformatics and Computational Biology: Bottlenecks and Options
By: CHI Insight Pharma Reports
The interdisciplinary fields of Bioinformatics and Computational Biology are locked in a high stakes race with analytical instrument developers and innovators. The pace and scope of change in many fields of biomedical research rivals what
|
more...
|
6/1/2009
|
$2,995.00
|
|
Approaches to Reducing Phase II Attrition
By: CHI Insight Pharma Reports
Phase II is the critical development stage in which most clinical attrition occurs. This report focuses on approaches to improving R&D productivity in the pharmaceutical and biotechnology industries and considers:
Leading-edge strategies being pursued
|
more...
|
5/1/2009
|
$2,995.00
|
|
Direct-To-Consumer Genetic Testing: Business Prospects in the United States
By: CHI Insight Pharma Reports
The current marketplace for direct-to-consumer (DTC) genetic testing is very dynamic and fluid. At least 42 DTC genetic testing companies have been identified to date, and additional market entrants are likely. Firms marketing and selling
|
more...
|
3/1/2009
|
$2,995.00
|
|
Medicinal Chemistry for Drug Discovery: Significance of Recent Trends
By: CHI Insight Pharma Reports
A thorough analysis of recent trends in medicinal chemistry and evaluation of their significance for advancing productivity in drug discovery is presented. This report includes:
A critical evaluation of chemical and computational technological modalities,
|
more...
|
3/1/2009
|
$2,995.00
|
|
Protease Inhibitors: Innovation Drives Drug Pipeline
By: CHI Insight Pharma Reports
Proteases constitute one of the largest potential drug target enzyme families, with 647 human gene products incorporating protease sequences and mutated proteases having been identified. In addition, there are many more proteases found in
|
more...
|
2/1/2009
|
$2,995.00
|
|
Molecular Diagnostics: A Dynamic and Rapidly Broadening Market
By: CHI Insight Pharma Reports
Molecular diagnostic applications in the areas of oncology, personalized medicine, inherited disorders, prediction of genetic disease risk, and many others are rapidly increasing in number as this burgeoning field expands beyond infectious disease testing. This
|
more...
|
1/1/2009
|
$2,995.00
|
|
European Clinical Trial Site Options: An Insider's Analysis
By: CHI Insight Pharma Reports
A vast new opportunity for clinical trials has emerged in Europe as a result of the collapse of the Soviet Union and events during the last decade of the 20th century. The result is the
|
more...
|
12/1/2008
|
$2,995.00
|
|
Biomedical Imaging: From Drug Target Discovery to Medical Diagnostics
By: CHI Insight Pharma Reports
Molecular imaging has become an increasingly indispensable tool in life sciences basic research, in translational medicine, and in routine medical diagnostics. This Biomedical Imaging report covers its top applications areas: medical diagnosis and translational research
|
more...
|
12/1/2008
|
$2,995.00
|
|
Neurodegenerative Diseases: Next-Generation Drugs for Four Major Disorders
By: CHI Insight Pharma Reports
Neurodegenerative diseases are drawing immense interest from the pharmaceutical industry and have inspired heavy competition in the race to introduce the next generation of improved drugs. Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral
|
more...
|
12/1/2008
|
$2,995.00
|
|
Conducting Clinical Trials in Europe: An Insider’s Analysis
By: CHI Insight Pharma Reports
A vast new opportunity for clinical trials has emerged in Europe as a result of the collapse of the Soviet Union and events during the last decade of the 20th century. The result is the
|
more...
|
12/1/2008
|
$2,995.00
|
|
Stem Cells Come of Age
By: CHI Insight Pharma Reports
Commercialization of stem cells can potentially help to treat an astounding variety of medical conditions. After a slow start, the stem cell age is finally poised to begin, as numerous factors converge to catapult stem
|
more...
|
11/1/2008
|
$2,995.00
|
|
Immunotherapies and Vaccines for Cancer and Infectious Diseases Report
By: CHI Insight Pharma Reports
The field of therapeutic vaccines and immunotherapies is rapidly emerging as a promising area. Use of passive immunotherapy (i.e., antibody) products, for prevention of infection or for treatment of many diseases, including cancer, is widespread.
|
more...
|
10/1/2008
|
$2,995.00
|
|
GPCRs: Dawn of a New Era?
By: CHI Insight Pharma Reports
Current advances in functional screening methodologies, medicinal chemistry, and structure-based drug design have generated large increases in the number and diversity of GPCR drug targets. Furthermore, basic research advances have opened the way for still
|
more...
|
10/1/2008
|
$2,995.00
|
|
Obesity Drug Pipeline: Developing Therapies for a Complex Disease
By: CHI Insight Pharma Reports
The prevalence of overweight and obesity is increasing at an alarming rate worldwide, driven by social and economic changes. Obesity is involved in the pathogenesis of major diseases, especially diabetes and cardiovascular disease. Yet there
|
more...
|
9/23/2008
|
$2,995.00
|
|
Strategic Management of Resources and Portfolios
By: CHI Insight Pharma Reports
As a company develops its business, resources will always be limited and risk will always be involved. This is especially true for companies operating in the high-risk life science industry. To stay on top of
|
more...
|
8/1/2008
|
$2,995.00
|
|
Cancer Biomarkers: Adoption Is Driving Growth
By: CHI Insight Pharma Reports
Aggressive adoption of cancer biomarkers will accelerate the growth of commercial markets for these products. This new report offers in-depth analysis of:
The current cancer biomarker products, applications, and markets
Key validation and
|
more...
|
7/1/2008
|
$2,995.00
|
|
Antibiotic R&D: Resolving the Paradox between Unmet Medical Need and Commercial Incentive
By: CHI Insight Pharma Reports
Antibiotic R&D:
Resolving the Paradox between Unmet Medical Need and Commercial Incentive
Author: Leslie A. Pray, PhD
The current crisis in antibiotic R&D is attributed to an industry pipeline with few late-stage candidates capable
|
more...
|
7/1/2008
|
$2,995.00
|
|
Title
|
Published
|
Price
|
(0 items)
